Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949940 | 0.90 | LMNA (0.35) | SMN1; SMN2LMNA | |
| SCHEMBL1950273 | 0.90 | MT-CO2 (0.35) | SMN1; SMN2LMNACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1947566 | 0.89 | LMNA (0.32) | SMN1; SMN2LMNA | |
| SCHEMBL1947495 | 0.89 | LMNA (0.34) | SMN1; SMN2LMNA | |
| SCHEMBL1439326 | 0.89 | MLYCD (0.33) | SMN1; SMN2LMNATSHRALDH1A1POLB | |
| SCHEMBL1948092 | 0.87 | MLYCD (0.36) | SMN1; SMN2LMNATSHRALDH1A1MAPT | |
| SCHEMBL1949957 | 0.86 | TSPO (0.35) | SMN1; SMN2LMNAALDH1A1POLBMAPT | |
| SCHEMBL6519022 | 0.85 | ALDH1A1 (0.36) | SMN1; SMN2LMNAALDH1A1POLBNPSR1 | |
| SCHEMBL1950109 | 0.82 | ALDH1A1 (0.33) | SMN1; SMN2LMNACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1949941 | 0.79 | LMNA (0.34) | SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | SMN1; SMN2 1538/4885LMNA 95/4885CYP2D6 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.